Trial Profile
Sofosbuvir Plus Ribavirin Without Interferon For Treatment of Acute HCV in HIV-1 Infected Individuals (SWIFT-C)
Status:
Completed
Phase of Trial:
Phase I
Latest Information Update: 06 Nov 2021
Price :
$35
*
At a glance
- Drugs Ledipasvir/sofosbuvir (Primary) ; Sofosbuvir (Primary) ; Ribavirin
- Indications Hepatitis C
- Focus Adverse reactions; Therapeutic Use
- Acronyms SWIFT-C
- 09 May 2018 Results assessing effect of sofosbuvir-based HCV treatment on plasma concentrations of tenofovir and cellular concentrations of tenofovir diphosphate, were published in the Journal of Antimicrobial Chemotherapy.
- 24 Oct 2017 Results assessing 8 weeks of ledipasvir/sofosbuvir therapy in HIV-infected men with genotype 1 or 4 HCV infection, of the presented at The Liver Meeting 2017: 68th Annual Meeting of the American Association for the Study of Liver Diseases
- 14 Jun 2017 Status changed from active, no longer recruiting to completed.